2Fleckenstein A, Antihypertensive and arterial anticalcinotic effect of calcium antagonist [J]. Am. J. Cardiol, 1986:57(7):1D.
3Muller F B, Calcium antagonist-a-new concept for treating essential hypertension [J]. Am. J. Cardiol, 1986:57(7):50D.
4Angelico P, Guarneri L, Ceonardi A [J]. J. Pharm. Pharmacol, 1999,51 (6):709-714.
5Pharma Market. Letter,2000,11 (13):2610.
6Nardi D, Leonardi A, Graziani G, et al. N-(3,3-Diphenylpropyl) aminoethyl esters of 1,4-dithydro-2,6-dimethylpyridine-3,5-diearboxylieacid, compositions and use[P]. US4705797,1987-10-10.
7Kansara R, Patel N, Rehani R, et al. A process for the preparation of 1, 4-dihydropyridine-3,5-dicarbo-xylie acid deri-vative [P]. WO2005/ 107374A2, 2005-11-17.
8Dixit G, Sharma K, Pranhan N, et al. Lereanidipine hydrochloride polymorphs and an improved process for preparation of 1,1, N-trimethyl-N-(3, 3-diphenylpropyl)-2-aminoethyl aeetoaeetate [P]. WO2008107797 A2,2008-09-12.
9Leonardi A, Motta G. A process for the preparation of Lereanidipine hydroehloride [P]. WO96/35668,1996-11-14.
10Adam Bor, Gyoergy Orose, Andrea B, et al. A process for producing Lercanidipine[P]. EP1860102, 2007-11-28.
